Mylan Lowered to Neutral at Citigroup Inc. (MYL)
Mylan (NYSE:MYL) was downgraded by equities researchers at Citigroup Inc. from a “buy” rating to a “neutral” rating in a research report issued on Friday, TheFlyOnTheWall.com reports. They currently have a $57.00 price objective on the stock, down from their previous price objective of $61.00. Citigroup Inc.’s price target indicates a potential upside of 10.17% from the company’s current price.
A number of other firms have also recently commented on MYL. Analysts at Deutsche Bank initiated coverage on shares of Mylan in a research note on Tuesday. They set a “buy” rating and a $67.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Mylan from $65.00 to $68.00 in a research note on Tuesday, July 15th. They now have an “overweight” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Mylan in a research note on Wednesday, June 18th. They now have a $53.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $52.58.
Shares of Mylan (NYSE:MYL) opened at 51.74 on Friday. Mylan has a 52-week low of $33.03 and a 52-week high of $57.52. The stock has a 50-day moving average of $51.0 and a 200-day moving average of $49.32. The company has a market cap of $19.337 billion and a price-to-earnings ratio of 32.42.
Mylan Inc (NYSE:MYL) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.